Aug. 14 at 1:19 PM
$ALT is underway with its phase 3 MASH trial, although a result might not come until 2029. There is a phase 2 in alcohol-associated liver disease on tap for 2027, with a recent study in alcohol use disorder producing positive results.
$MDGL
https://seekingalpha.com/article/4936237-altimmune-pemvidutide-performs-but-a-long-wait-ahead
